


**EXHIBIT 5 TO NUVASIVE, INC.'S
NOTICE OF LODGMENT OF WITNESS
DEPOSITION DESIGNATION CLIP REPORTS**

NuVasive v. Alphatec

 **Howell, Kelli (Vol. 01) - 06/01/2018**

1 CLIP (RUNNING 00:00:51.421)

 Other than neuromonitoring, is there ...

KH093L15

1 SEGMENT (RUNNING 00:00:51.421)



1. PAGE 93:15 TO 94:04 (RUNNING 00:00:51.421)

15 Q. Other than neuromonitoring, is there
16 anything else about the XLIF platform that
17 contributes to desirable clinical outcomes?
18 A. Again, from an assembly standpoint, all
19 of it. Does a surgeon like certain features to
20 make it less fiddly, that saves them time in the
21 procedure, familiarity with the system. Again,
22 being an early entrant to the market, having the
23 benefit of experience with the platform, gaining
24 those biases to certain design elements of it, our
25 features of functionality or how things work during
00094:01 the procedure. All of that, I think, results in
02 what the ultimate outcome looks like and the
03 ability to demonstrate whether an outcome is better
04 or worse.

TOTAL: 1 CLIP FROM 1 DEPOSITION (RUNNING 00:00:51.421)